Researchers at the University of California, Davis have developed a plant-based, fusion protein for use in the treatment of inflammatory diseases.
Inflammatory diseases - such as alpha-1 anti-trypsin deficiency (AATD) and cystic fibrosis (CF) – are currently treated using plasma-derived, IV replacement therapies. Although such therapies are safe and effective, they have limitations due to cost, purity specifications, and limited availability. There is a need for a treatment that avoids the complexity and cost of collection, purification, sterilization, preservation and distribution of plasma.
Researchers at the University of California, Davis have developed a plant-based, elafin-fusion protein that can be used as a potential therapeutic to treat patients with inflammatory diseases. This therapeutic provides a cost-effective and stable treatment option for patients who either lack access to plasma-derived, IV replacement therapies or are seeking a lower cost, alternative therapy. The protein is resistant to proteolytic cleavage and oxidation, and has anti-inflammatory properties. Additionally, the therapeutic exhibits human-like glycosylation, has a longer half-life than other treatments and can be delivered via infusion or inhalation.
|United States Of America||Issued Patent||10,918,703||02/16/2021||2016-656|
Elafin, Fusion proteins, Anti-protease augmentation, Inflammatory disease, Inflammatory lung disease, Inflammatory pulmonary disease, Alpha-1 antitrypsin deficiency, AATD, Cystic fibrosis, Chronic obstructive pulmonary disease, COPD, Plasma-derived IV rep